To read the full story, subscribe or sign in.

Harpoon lands $45M in series B funding for trispecific protein drugs

May 26, 2017

DUBLIN – Harpoon Therapeutics Inc. has landed a $45 million series B round to enable it to further develop its distinctive approach to the discovery of post-antibody scaffolds with multiple specificities.

BioWorld

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for March 5.

Gloved hand places sample tubes in PCR system

COVID-19 test makers are adapting for variants

BioWorld MedTech

As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for March 5.

Coronavirus vaccine/therapeutics illustration

Tonix looks to the past for the future of COVID-19 vaccines and testing

BioWorld MedTech

Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...